Emily Henkle is an epidemiologist and research assistant professor who in recent years has focused on projects related to pulmonary infectious disease. Her research has focused on nontuberculous mycobacteria – or NTM disease – along with pediatric Haemophilus influenzae and pneumococcal infection, infant influenza and adult influenza in healthcare workers. She approaches her research with both the individual and public health in mind, producing data on disease burden, incidence and natural history of disease.
Her most recent work has explored patient-centered research and health-related quality of life in patients with chronic NTM infection and underlying bronchiectasis. She is studying correlations between health-related quality of life measures and NTM disease activity and is measuring the efficacy of current treatments in relation to respiratory symptoms, physical functioning and fatigue.
She also manages a statewide special surveillance project with the Oregon Health Authority and coordinates enrollment and data collection for the Northwest NTM Biobank.
M.P.H., University of California Berkeley, 2000
Ph.D., Johns Hopkins Bloomberg School of Public Health, 2010
Awards and Honors
- 2007-2010, Pre-doctoral fellow, NEI Clinical Trials Training Grant
- 2016, Junior Investigator Award, ATS/ALA
- (Henkle) 01/01/17 – 12/31/18. American Thoracic Society/American Lung Association of the Mountain Pacific. Health-related quality of life as a clinical trial endpoint for nontuberculous mycobacteria disease. Role: Principal Investigator.
- 1013-OHSU (Henkle) 05/01/15 – 04/30/16. Patient-Centered Outcomes Research Institute (PCORI). NTM Research Consortium Stakeholder Engagement and Planning Meeting. Role: Project Lead.
- FD -R-05401-01-A1 (Winthrop) 09/01/16 – 07/31/20. Food and Drug Administration P2 Study of Clofazimine for Pulmonary M. avium Disease IND 125,266 (1/5/2015). Role: Co-investigator.
- CER-1503-29191 (Winthrop) 01/01/16 – 06/30/18. Patient-Centered Outcomes Research Institute (PCORI). Comparative effectiveness and safety of inhaled corticosteroids and antimicrobial compounds for non-CF bronchiectasis. Role: Co-investigator/Project Director
- DS-311495 (Winthrop) 07/01/14 – 06/30/17. American Lung Association Natural History of Nontuberculous Mycobacterial Pulmonary Disease and Immune Correlates of Disease Progression. Role: Co-investigator/Project Director
- 2561-OHSU (Winthrop) 01/01/16 – 12/31/16. Patient-Centered Outcomes Research Institute (PCORI). Non-cystic fibrosis (CF) bronchiectasis patient network and research roadmap. Role: Co-investigator/Project Director.
¹ CEPH Primary Instructional Faculty
² CEPH Non-Primary Instructional Faculty